March 26, 2019
Representatives from the Japan Medical Association (JMA) on a health ministry drug safety panel opposed on March 22 to reclassify a switch-OTC version of Mochida Pharmaceutical’s hyperlipidemia treatment Epadel (ethyl icosapentate), which is currently classified as a “ behind-the-counter (BTC)...read more